BioGaia AB (LTS:0GTN)
kr 105.6 -0.5 (-0.47%) Market Cap: 10.72 Bil Enterprise Value: 9.61 Bil PE Ratio: 31.77 PB Ratio: 6.63 GF Score: 90/100

Q2 2023 Biogaia AB Earnings Call Transcript

Jul 21, 2023 / 07:30AM GMT
Release Date Price: kr101.7 (-0.71%)
Operator

Welcome to BioGaia Q2 Conference Call for 2023. (Operator Instructions) Now I will hand the conference over to CEO, Isabelle Ducellier. Please go ahead.

Isabelle Valerie Ghislaine Ducellier;publ;CEO;President
BioGaia AB

()-&

Thank you, and good morning, everybody, for this interim management statement Q2 2023. So as an executive summary, just to point out the -- outline the main results in terms of sales we have SEK 315 million for the quarter 2. We can show a growth of 9%, 2% being organic and the rest currency effect driven by a strong growth in Americas, a slight decrease in Europe and relative growth in APAC, and I will come back to that later. Regarding the EBIT, it's a bit under the -- last year at minus 6% at SEK 95 million, but we maintained an EBIT margin of 30%.

Starting with the key events. I would like to emphasize on the third press release we published on the 5th of July informing the market about a very interesting clinical study. We've been running with Orebro University here in Sweden

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot